FOXO Technologies Inc. Provides Update on Recent Accomplishments and Business Strategy

FOXO Technologies Inc., a Delaware corporation trading on the NYSE American under the symbol FOXO, recently released a press release sharing insights into the company’s achievements and strategic direction. The report included a shareholder letter from Seamus Lagan, the newly appointed CEO, highlighting accomplishments in recent months and outlining plans for 2025 and beyond.

The company disclosed that the shareholder meeting held on January 17, 2025, marked the fulfillment of 2024 acquisition agreements, resulting in a change of control. The progress made during the second half of 2024 was instrumental in steering the company towards a successful turnaround, paving the way for a potentially profitable revenue-driven enterprise.

Transitioning from minimal net revenues, FOXO Technologies has acquired businesses with the potential to generate over $20 million in profitable net revenues annually. To address a shareholder deficit exceeding $17 million as of September 30, 2024, significant debt restructuring was undertaken in the fourth quarter. This restructuring boosted shareholders’ equity by more than $21 million, fostering compliance with NYSE American’s listing rules.

Looking ahead to 2025, FOXO Technologies plans to focus on expanding its acquired rural hospital and behavioral health businesses while exploring strategies to monetize its existing epigenetics division. The company is actively engaging in discussions for further acquisition opportunities in the healthcare sector, including senior living.

Key points of interest for the upcoming period include the timely filing of the 2024 audited financials, exploring capital procurement options for executing the business strategy, ongoing negotiation for debt conversions to equity, potential additional acquisitions, and enhancements to the company’s web presence for improved communication with stakeholders and interested parties.

FOXO Technologies runs three primary businesses:

1. **Epigenetics**: FOXO Lab’s, a leading entity in epigenetic biomarker discovery and commercialization, leveraging extensive data and AI technology for personalized healthcare solutions. A direct-to-consumer prognostic tool is in the pipeline to enhance well-being.

2. **Myrtle Recovery Centers**: Operating a behavioral health facility in Tennessee, Myrtle offers inpatient and outpatient services, aiming for profitable growth and service replication in various locations.

3. **Scott County Community Hospital**: Acquired in 2024, this critical access designation facility in Tennessee provides a range of medical services, with plans in place for additional hospital facilities in the region.

The recent achievements indicate a significant turnaround for FOXO Technologies, presenting promising opportunities for the company and its shareholders. Challenges loom ahead in 2025, and the management team under the leadership of CEO Seamus Lagan expresses gratitude for ongoing shareholder support.

The press release contained forward-looking statements emphasizing the company’s vision and goals while highlighting potential risks and uncertainties inherent in the business landscape. FOXO Technologies commits to transparency and regulatory compliance in all its operations and disclosures.

Contact:
Sebastien Sainsbury
[email protected]
(561) 485-0151

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read FOXO Technologies’s 8K filing here.

About FOXO Technologies

FOXO Technologies Inc engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging.